We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement
News

Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement

Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement
News

Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina and Oxford Nanopore Technologies have announced a strategic alliance including a commercialization agreement and equity investment.

Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products developed by Oxford Nanopore for DNA sequencing into the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales.

Oxford Nanopore’s new generation sequencing system uses protein nanopores coupled with a processive enzyme. This system is designed for direct electrical identification of DNA bases at the single-molecule level, without the need for fluorescent labels.

Currently in development, this technology has the potential to provide substantial advantages over current sequencing approaches, not only in speed and cost but also in simplicity and versatility of overall workflow.

As part of the agreement, Illumina made an equity investment of $18.0 million (£11.8 million), which will be used to accelerate the development of BASE™ Technology. Illumina has also agreed to make an additional equity investment upon the achievement of a specific technical milestone.
Advertisement